The researchers argue that the evidence used to approve the product — called Abilify MyCite — was not only weak, but failed to demonstrate the technology improves adherence, a key point if the goal is to improve health outcomes. In other public health news: neuron research, seasickness, surgery, scooter safety, broken heart syndrome, and more.
from Kaiser Health News https://ift.tt/2XTADXy
Rose
0 comments:
Post a Comment